XTL Biopharmaceuticals Ltd. (FRA:H2K2)
Germany
· Delayed Price · Currency is EUR 0.675
+0.030 (4.65%)
At close: Dec 4, 2025
XTL Biopharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 0.45 | - | - | - | - | Upgrade
|
| Cost of Revenue | 0.45 | - | - | - | - | Upgrade
|
| Gross Profit | 0 | - | - | - | - | Upgrade
|
| Selling, General & Admin | 2.08 | 0.73 | 0.85 | 1 | 0.91 | Upgrade
|
| Research & Development | 0.1 | 0.03 | 0.03 | 0.03 | 0.04 | Upgrade
|
| Operating Expenses | 2.18 | 0.77 | 0.88 | 1.03 | 0.95 | Upgrade
|
| Operating Income | -2.17 | -0.77 | -0.88 | -1.03 | -0.95 | Upgrade
|
| Interest Expense | -0.03 | - | - | - | - | Upgrade
|
| Interest & Investment Income | 0.03 | 0.04 | 0.04 | 0.01 | 0.03 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.03 | -0.03 | -0.02 | 0.01 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.06 | -0 | -0.01 | 0.7 | -2.19 | Upgrade
|
| EBT Excluding Unusual Items | -2.25 | -0.76 | -0.87 | -0.31 | -3.09 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.09 | -1.02 | -0.48 | 0.75 | 0.14 | Upgrade
|
| Pretax Income | -1.16 | -1.78 | -1.35 | 0.44 | -2.95 | Upgrade
|
| Income Tax Expense | -0.13 | - | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -1.03 | -1.78 | -1.35 | 0.44 | -2.95 | Upgrade
|
| Net Income | -1.03 | -1.78 | -1.35 | 0.44 | -2.95 | Upgrade
|
| Net Income to Common | -1.03 | -1.78 | -1.35 | 0.44 | -2.95 | Upgrade
|
| Shares Outstanding (Basic) | 673 | 545 | 545 | 532 | 514 | Upgrade
|
| Shares Outstanding (Diluted) | 704 | 545 | 545 | 616 | 514 | Upgrade
|
| Shares Change (YoY) | 29.23% | -0.00% | -11.48% | 19.71% | - | Upgrade
|
| EPS (Basic) | -0.00 | -0.00 | -0.00 | 0.00 | -0.01 | Upgrade
|
| EPS (Diluted) | -0.00 | -0.00 | -0.00 | 0.00 | -0.01 | Upgrade
|
| Free Cash Flow | -1.67 | -0.71 | -0.9 | -1.05 | -0.85 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | Upgrade
|
| Gross Margin | 0.66% | - | - | - | - | Upgrade
|
| Operating Margin | -481.60% | - | - | - | - | Upgrade
|
| Profit Margin | -227.72% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | -370.73% | - | - | - | - | Upgrade
|
| EBITDA | -1.97 | -0.76 | -0.88 | -1.03 | -0.95 | Upgrade
|
| D&A For EBITDA | 0.2 | 0 | 0 | 0 | 0 | Upgrade
|
| EBIT | -2.17 | -0.77 | -0.88 | -1.03 | -0.95 | Upgrade
|
| Advertising Expenses | 0.16 | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.